TY - JOUR
T1 - Plasma Lipid Profiling Increased Cardiometabolic Risks in Acute Myeloid Leukaemia Patients Pre- and Post-chemotherapy
AU - 謝, 淑芳(Shu-Fang Hsieh)
AU - 孫, 宏羽(Hung-Yu Sun)
AU - 王, 信沺(Sin-Tian Wang)
AU - 李, 欣學(Sin-Syue Li)
AU - 許, 雅婷(Ya-Ting Hsu)
AU - 林, 韋伶(Wei-Ling Lin)
AU - 楊, 孔嘉(Kung-Chia Young)
PY - 2022/6/30
Y1 - 2022/6/30
N2 - Background: Haematological malignancy affects lipid homeostasis representing elevated risks of cardiometabolic diseases. This study investigated the alteration of plasma lipids/lipoproteins and the underlying regulation mechanism. Materials and Methods: Blood samples were collected from acute myeloid leukaemia (AML) patients pre-and post-chemotherapy and matched controls. Triglyceride (TG), total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-c), low-density-lipoprotein cholesterol (LDL-c) and apolipoproteins (apo) were quantified in plasma and lipoprotein-density-gradient fractions. The cardiometabolic risks and lipid loads were assessed. Results: Dyslipidaemia was revealed in 75% of AML patients pre-therapy by reduction of HDL-c and in 85% post-therapy by diverse combined patterns. Compared to the controls, AML patients exhibited increased plasma TG and cardiometabolic risks both pre- and post-therapy. The plasma TC, HDL-c, apoAI, B-100, CIII and J were decreased pre-therapy but were restored post-therapy. The plasma TG concentration was positively correlated with LDL-TG load, whereas plasma TC was positively correlated with HDL-c. Furthermore, the fractionated very-low-density lipoprotein (VLDL)-TG load was lower but LDL-TG load was higher in AML patients than in the controls, suggesting that circulating TG hydrolysis might be impaired from VLDL conversion to LDL. Conclusion: The plasma lipid profiles in AML were aberrant and predicted high cardiometabolic risks, which might need further follow-up attentions.
AB - Background: Haematological malignancy affects lipid homeostasis representing elevated risks of cardiometabolic diseases. This study investigated the alteration of plasma lipids/lipoproteins and the underlying regulation mechanism. Materials and Methods: Blood samples were collected from acute myeloid leukaemia (AML) patients pre-and post-chemotherapy and matched controls. Triglyceride (TG), total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-c), low-density-lipoprotein cholesterol (LDL-c) and apolipoproteins (apo) were quantified in plasma and lipoprotein-density-gradient fractions. The cardiometabolic risks and lipid loads were assessed. Results: Dyslipidaemia was revealed in 75% of AML patients pre-therapy by reduction of HDL-c and in 85% post-therapy by diverse combined patterns. Compared to the controls, AML patients exhibited increased plasma TG and cardiometabolic risks both pre- and post-therapy. The plasma TC, HDL-c, apoAI, B-100, CIII and J were decreased pre-therapy but were restored post-therapy. The plasma TG concentration was positively correlated with LDL-TG load, whereas plasma TC was positively correlated with HDL-c. Furthermore, the fractionated very-low-density lipoprotein (VLDL)-TG load was lower but LDL-TG load was higher in AML patients than in the controls, suggesting that circulating TG hydrolysis might be impaired from VLDL conversion to LDL. Conclusion: The plasma lipid profiles in AML were aberrant and predicted high cardiometabolic risks, which might need further follow-up attentions.
M3 - Article
SN - 1013-7653
VL - 34
SP - 79
EP - 91
JO - Journal of Biomedical & Laboratory Sciences ＝ 生物醫學暨檢驗科學雜誌
JF - Journal of Biomedical & Laboratory Sciences ＝ 生物醫學暨檢驗科學雜誌
IS - 2
ER -